118 / 510
Cuidados
Continuos
117
BIBLIOGRAFIA
Knight K, Wade S, Balducci L. Prevalence and outcomes of anemia in cancer: a systematic review of
the literature. Am J Med 2004;116 Suppl 7A: 11S-26S.
Schwartz RN. Anemia in patients with cancer: incidente, causes, impact, management, and use of
treatment guidelines and protocols. Am J Health Syst Pharm 2007; 64: S5-13; quiz S28-30.
Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, et al. The European
Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence,
incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004; 40 (15): 2293-306.
Aapro M, Osterborg A, Gascón P, Ludwig H, Beguin Y. Prevalence and Management of cancer-
related anaemia, iron deficiency and the specific role of i.v, iron. Ann Oncol. 2012 Aug; 23(8): 1954-62.
Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for
solid tumors. Oncologist. 2012; 17(5): 715-24.
Stack G, Judge JV, Snyder EL. Febrile and non-immune transfusion reactions. In: Principles
of Transfusion Medicine, Rossi EC, Simon TL, Moss GS, Gould SA (Eds), Williams and Wilkins,
Philadelphia 1996. p.778.
Winslow RM, Intaglietta M. Red cell age and loss of function: advance or SNO-job? Transfusion
2008; 48 (3): 411-4.
Erythropoietin or darbepoetin for patients with cancer. Tonia T, Mettler A, Robert N, Schwarzer
G, Seidenfeld J, Weingart O, et al. Erythropoietin or arbepoetin for patients with cancer. Cochrane
Database Sust Rev. 2012; 12: CD003407.
Grant MD, Piper M, Bohlius j; Tonia T, Robert N, Vats V, et al. Epoetin and Darbepoetin for managing
anemia in patients urdergoing cancer treatment: comparative effectiveness update [Internet ].
Rockville (MD): Agency for Healthcare research an quality (US); 2013. Report No. 13-EHC077-EF.
Yasuda Y, Fujita Y, Matsuo T, Koinuma S, Hara S, Tazaki A, et al. Erythropoietin regulates tumourr
growth of human malignancies. Carcinogenesis. 2003; 24 (6): 1021-9.
Douglas Rizzo J, Brouwers M, Hurley P, Seindenfeld J, Arcasoy M.O, Spivak J.L, et al. American
Society of Clinical Oncology/ American Society of Hematology Clinical Practise Guideline Update
on the Use of Epoetin and Darbapoetin in Adult Patients with Cancer. Journal of Clinical Oncology.
(2010); 28 (33): 4996-5010.
Aapro MS, Link H. September 2007 Update on EORTC Guidelines and Anemia Management with
Erythropoiesis-Stimulating Agents. The Oncologist 2008; 13 (suppl 3): 33-36.
Alberola V, Carrato A, Diaz-Rubio E, Gascón P, González M, Martín M, et al. Spanish Society of
Medical Oncology consensus on the use of erythropoietic stimulating agents in anaemic cancer
patients. Clin Transl Oncol (2009) 11 (11): 727-736.
National Comprehensive Cancer Network. Practise Guidelines in Oncology. Cancer-and-
Chemotherapy-induced-Anemia. Version 2.2014.
Leyland-Jones B, BEST investigators and Study Group. Breast cancer trial with erythropoietin
terminates unexpectedly. Lancet Oncol 2003; 4 (8): 459-460.
1.
2.
3.
4.
5.
6.
7.
8.
9.
10.
11.
12.
13.
14.
15.